期刊文献+

2型糖尿病血脂异常的治疗进展 被引量:18

下载PDF
导出
摘要 血脂异常是糖尿病并发大血管病变的主要危险因素之一.糖尿病血脂异常的特点为甘油三酯(TG)增高、高密度脂蛋白胆固醇(HDL-C) 降低、低密度脂蛋白胆固醇(LDL-C)轻、中度增高,LDL-C亚型小而密LDL(sLDL-C)比例增高,加之氧化的低密度脂蛋白(Ox LDL)增多.糖尿病已列为冠心病的等危症,血脂异常的治疗目标等同于冠心病患者.糖尿病患者血脂异常的治疗首先应使LDL-C达到目标值,即 LDL-C<2.6 mmol/L(1 g/L),糖尿病合并心血管疾病患者建议使用他汀类药物治疗,并建议将LDL-C降到较低水平LDL-C<1.81 mmol/L (0.7 g/L).对糖尿病患者进行降脂治疗,能显著降低心血管疾病风险.
作者 王学美
出处 《世界华人消化杂志》 CAS 北大核心 2006年第4期359-364,共6页 World Chinese Journal of Digestology
  • 相关文献

参考文献18

  • 1尹香君,焦淑芳,李红,谢瑾,王瑜,吴立军.北京地区2型糖尿病代谢异常及血压控制情况[J].中国慢性病预防与控制,2004,12(2):57-60. 被引量:20
  • 2Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus- United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316:823-828.
  • 3Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with noninsulin-dependent diabetes. Circulation 1993; 88:1421-1430.
  • 4Pyorala K, Pedersen TR, Kjekshus J, Faergeman O,Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
  • 5Goldberg RB, Mellies MJ, Sacks FM, Moye LA,Howard BV, Howard WJ, Davis BR, Cole TG,Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivorswith average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE)trial. The Care Investigators. Circulation 1998; 98:2513-2519.
  • 6Collins R, Armitage J, Parish S, Sleigh P, Peto R.MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet 2003; 361:2005-2016.
  • 7Serruys PW, de Feyter P, Macaya C, Kokott N,Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-3222.
  • 8Colhoun HM, Betteridge DJ, Durrington PN,Hitman GA, Neil HA, Livingstone SJ, ThomasonMJ, Mackness MI, Charlton-Menys V, Fuller JH.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
  • 9Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
  • 10Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR,Kashyap ML, Hershman JM, Wexler LF, Rubins HB.Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.

二级参考文献6

共引文献79

同被引文献175

引证文献18

二级引证文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部